von Willebrand factor – Factor VIII binding interface (VWF-FVIII interface)

The von Willebrand factor (VWF) – Factor VIII (FVIII) binding interface is a specialized protein-protein interaction site essential for maintaining hemostatic balance. VWF acts as a carrier protein for FVIII, binding it with high affinity primarily through the VWF D' and D3 domains (UniProt P04275). This interaction protects FVIII from premature proteolytic degradation by activated protein C and rapid clearance from the plasma, effectively extending the half-life of FVIII in circulation (PubMed 32691015). In the context of Hemophilia A, the endogenous VWF-FVIII binding limit acts as a pharmacokinetic ceiling for the half-life of traditional replacement therapies. Novel therapeutics like Efanesoctocog alfa (BIVV001) utilize a recombinant VWF D'D3 fragment to shield FVIII, bypassing the need for endogenous VWF binding and significantly extending the drug's duration of action (NEJM 388:310-318). Mutations at this interface are the primary cause of von Willebrand disease type 2N (Normandy), where FVIII cannot bind to VWF, leading to clinical symptoms mimicking Hemophilia A. This interface is a key focus for bioengineering efforts aimed at overcoming the pharmacokinetic limitations of clotting factor concentrates.

Other names

VWF D'D3 domainFactor VIII binding site on VWFVWF-FVIII complexVWF-F8 interaction site

Stabilization and protection of Factor VIII from premature clearance and proteolytic degradation through high-affinity binding to the VWF D'D3 domains.